Opportunities and challenges following approval of resmetirom for MASH liver disease
Jeffrey V. Lazarus, Dana Ivancovsky‐Wajcman, Henry E. Mark, Zobair M. Younossi, Christopher J. Kopka, Nevin Cohen, Meena B. Bansal, Michael Betel, Paul Brennan
Topics & Concepts
SteatohepatitisFood and drug administrationDrug approvalMedicineDiseaseDrugApproved drugPharmacologyFatty liverInternal medicineLiver Disease Diagnosis and TreatmentDiet and metabolism studiesMetabolism, Diabetes, and Cancer